Connection

JOANNA YI to Leukemia, Myeloid, Acute

This is a "connection" page, showing publications JOANNA YI has written about Leukemia, Myeloid, Acute.
Connection Strength

1.116
  1. Defining the transcriptional control of pediatric AML highlights RARA as a superenhancer-regulated druggable dependency. Blood Adv. 2021 12 14; 5(23):4864-4876.
    View in: PubMed
    Score: 0.467
  2. FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML. Blood. 2025 Nov 20; 146(21):2608-2611.
    View in: PubMed
    Score: 0.153
  3. MLL oncoprotein levels influence leukemia lineage identities. Nat Commun. 2024 10 29; 15(1):9341.
    View in: PubMed
    Score: 0.143
  4. A distinct core regulatory module enforces oncogene expression in KMT2A-rearranged leukemia. Genes Dev. 2022 03 01; 36(5-6):368-389.
    View in: PubMed
    Score: 0.118
  5. An oncogenic enhancer encodes selective selenium dependency in AML. Cell Stem Cell. 2022 03 03; 29(3):386-399.e7.
    View in: PubMed
    Score: 0.118
  6. Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia. Blood Adv. 2021 12 14; 5(23):5215-5219.
    View in: PubMed
    Score: 0.117
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.